Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting

Daratumumab (Dara), a multiple myeloma (MM) therapy, is an antibody against the surface receptor CD38, which is expressed not only on plasma cells but also on NK cells and monocytes. Correlative data have highlighted the immune-modulatory role of Dara, despite the paradoxical observation that Dara r...

Descripción completa

Detalles Bibliográficos
Autores principales: Viola, Domenico, Dona, Ada, Caserta, Enrico, Troadec, Estelle, Besi, Francesca, McDonald, Tinisha, Ghoda, Lucy, Gunes, Emine Gulsen, Sanchez, James F, Khalife, Jihane, Martella, Marianna, Karanes, Chatchada, Htut, Myo, Wang, Xiuli, Rosenzweig, Michael, Chowdhury, Arnab, Sborov, Douglas, Miles, Rodney R, Yazaki, Paul J., Ebner, Todd, Hofmeister, Craig C., Forman, Stephen J, Rosen, Steven T, Marcucci, Guido, Shively, John, Keats, Jonathan J, Krishnan, Amrita, Pichiorri, Flavia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572537/
https://www.ncbi.nlm.nih.gov/pubmed/32296125
http://dx.doi.org/10.1038/s41375-020-0810-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7572537/
https://www.ncbi.nlm.nih.gov/pubmed/32296125
http://dx.doi.org/10.1038/s41375-020-0810-4

Ejemplares similares